Theravance Biopharma (NASDAQ:TBPH) Now Covered by Jones Trading

Jones Trading initiated coverage on shares of Theravance Biopharma (NASDAQ:TBPH) in a research note issued to investors on Tuesday,Benzinga reports. The firm issued a buy rating and a $24.00 target price on the biopharmaceutical company’s stock.

TBPH has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th. Wall Street Zen raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Wednesday, May 14th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.50.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH opened at $10.60 on Tuesday. The company has a market cap of $530 million, a PE ratio of -8.98 and a beta of -0.09. Theravance Biopharma has a 12 month low of $7.44 and a 12 month high of $11.82. The company has a 50-day simple moving average of $9.65 and a 200-day simple moving average of $9.46.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.16). The firm had revenue of $15.39 million for the quarter, compared to analysts’ expectations of $28.08 million. Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. On average, analysts anticipate that Theravance Biopharma will post -1.09 EPS for the current year.

Insider Activity

In related news, SVP Rhonda Farnum sold 24,000 shares of Theravance Biopharma stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total value of $264,000.00. Following the completion of the sale, the senior vice president now owns 336,918 shares in the company, valued at approximately $3,706,098. The trade was a 6.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several hedge funds have recently bought and sold shares of the company. Aquatic Capital Management LLC acquired a new position in shares of Theravance Biopharma in the 4th quarter worth approximately $25,000. GAMMA Investing LLC boosted its holdings in shares of Theravance Biopharma by 1,201.8% during the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 3,281 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Theravance Biopharma during the fourth quarter worth approximately $69,000. AQR Capital Management LLC acquired a new stake in shares of Theravance Biopharma during the first quarter worth approximately $101,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Theravance Biopharma during the fourth quarter worth approximately $103,000. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.